Sinopharm Financial Statements From 2010 to 2024
| X2S Stock | EUR 2.64 0.04 1.54% |
Check Sinopharm Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinopharm Group's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sinopharm financial statements analysis is a perfect complement when working with Sinopharm Group Valuation or Volatility modules.
Sinopharm |
Sinopharm Group Co Company Shares Outstanding Analysis
Sinopharm Group's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Sinopharm Group Shares Outstanding | 1.34 B |
Most of Sinopharm Group's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Sinopharm Group Co has 1.34 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Distribution industry. The shares outstanding for all Germany stocks is 134.66% lower than that of the firm.
Sinopharm Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinopharm Group Co is roughly 3.62 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.About Sinopharm Group Financial Statements
Sinopharm Group stakeholders use historical fundamental indicators, such as Sinopharm Group's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sinopharm Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sinopharm Group's assets and liabilities are reflected in the revenues and expenses on Sinopharm Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sinopharm Group Co. Please read more on our technical analysis and fundamental analysis pages.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Sinopharm Stock
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.